Top Markets
Coin of the day
Aroa Biosurgery Limited Aroa Biosurgery Limited

Aroa Biosurgery Limited

ARX
Clasificación en acciones #20200
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated... Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
Precio por acción
$0.39848591
Capitalización bursátil
$137.67M
Cambio (1 día)
-1.74%
Cambio (1 año)
-3.96%
País
NZ
Comercio Aroa Biosurgery Limited (ARX)

Categoría

Ganancias de Aroa Biosurgery Limited (ARX)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Aroa Biosurgery Limited, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Aroa Biosurgery Limited desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
- -
DE